Multiparametric Prostate MRI for Local Staging
Yes, multiparametric prostate MRI (mpMRI) is indicated and should be used for local staging of prostate cancer across all risk groups. The prebiopsy MRI that was obtained for diagnosis provides the necessary local staging information 1.
Guideline-Based Recommendations
The 2024 EAU guidelines explicitly state to "use prebiopsy magnetic resonance imaging for local staging information" for any risk group 1. This represents a paradigm shift where the same MRI obtained before biopsy serves dual purposes: guiding targeted biopsies and providing T-staging information.
The 2022 AUA/ASTRO guidelines similarly recommend that clinicians should obtain pelvic mpMRI for patients with high-risk prostate cancer (Strong Recommendation) 2. For intermediate and low-risk disease, while not explicitly mandated for staging alone, the prebiopsy MRI already provides this information.
Why MRI Outperforms Clinical Staging
MRI demonstrates significantly superior performance compared to digital rectal examination (DRE) for detecting non-organ confined disease, with 51% sensitivity versus only 12% for DRE (p < 0.001), though at the cost of slightly lower specificity (82% vs 97%) 1. This improved discrimination leads to better prediction of biochemical recurrence-free survival through more accurate risk stratification 1.
mpMRI provides critical information about:
- Extraprostatic extension (EPE)
- Seminal vesicle invasion (SVI)
- Tumor location and extent
- Local organ involvement
T2-weighted imaging serves as the cornerstone sequence for local staging assessment 3, 4.
Important Caveats and Limitations
MRI has high specificity but limited sensitivity for detecting extraprostatic extension, seminal vesicle invasion, and lymph node metastases 3, 4. Real-world data from 2023 shows concerning performance: sensitivity ranges from only 2.9%-49.2% for various pathologic features, though specificity remains adequate at 89.1%-100% 5. This means MRI is better at ruling in disease when positive than ruling it out when negative.
The negative predictive value ranges from 56.3%-94.3%, meaning a negative MRI does not reliably exclude locally advanced disease 5. Therefore, mpMRI should not be used as the sole staging modality - clinical factors, PSA, grade group, and percentage of positive cores must be integrated into the overall risk assessment 5.
Practical Algorithm
For all patients with newly diagnosed prostate cancer:
Use the prebiopsy mpMRI (already obtained) for local T-staging information 1
For high-risk disease: Add cross-sectional abdominopelvic imaging and bone scan, or preferably PSMA PET/CT if available (Strong recommendation) 1, 2
For ISUP grade group 3 (intermediate-risk): Consider adding abdominopelvic imaging and bone scan, with PSMA PET/CT if available (Weak recommendation) 1
For low-risk disease: No additional staging imaging beyond the diagnostic mpMRI 1
Emerging Considerations
While biparametric MRI (without contrast) is being investigated to reduce costs and gadolinium exposure, multiparametric MRI remains the recommended standard for local staging 6. PSMA PET/MRI shows promise but currently offers no statistically significant advantage over mpMRI alone for local staging, though it excels at detecting nodal and distant metastases 7.